Blood Management Today Incorporating TEG
|
|
- Joanna Briggs
- 8 years ago
- Views:
Transcription
1 Blood Management Today Incorporating TEG AMSECT NABM meeting Mike Miller Manager Clinical Manager Hemostasis Training Haemonitics Rx Only 2011 Haemonetics Corporation. Haemonetics, TEG, RapidTEG and Thrombelastograph are trademarks or registered trademarks of Haemonetics Corporation in the USA, other countries, or both. PlateletMapping is a trademark of Cora Healthcare. Plavix is a registered trademark of Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. All other registered trademarks are the property of their respective owners. All rights reserved. TRN-PPT US(AA) Topics to Discuss Blood Management Today Traditional Hemostasis Case Study TEG Risk Stratification PlateletMapping Assay Case study Wrap up Haemonetics Corp
2 Blood Management Today A Common Goal Haemonetics Corp Haemonetics Corp
3 Observed variation in hospital-specific transfusion rates for primary isolated CABG surgery with cardiopulmonary bypass during 2008 (N = 798 sites) Bennett-Guerrero, et al. JAMA 2010; 304: Haemonetics Corp Almost 20 years ago, the study by Goodnough et al showed significant variability in transfusion practice in 540 patients who underwent cardiac surgery across 18 institutions and drew attention to this problem Haemonetics Corp
4 TEG..is there a clinical need? ACS NSQIP the American College of Surgeons National Surgical Quality Improvement Program 941,496 operations in 173 hospitals 15, patients t received 1 unit of fintraoperative ti transfusion 55 variables used in propensity scoring 11,855 matched pairs Complication No Transfusion Transfusion P value Mortality % Unless your patient is actively bleeding to death, it is simply best not to transfuse any blood products. Wound Problems <0.001 John B. Holcomb, MD University of Texas Health Science Center % Pulmonary % <0.001 Renal % <0.001 Cardiac % Sepsis % <0.001 Postop LOS (days) <0.001 Ferraris, VA, et al. Arch Surg 2012; 147: Haemonetics Corp Traditional Hemostasis Current Coag Testing vs TEG Haemonetics Corp
5 What does the literature say about traditional coagulation testing? Elevated activated partial thromboplastin time does not correlate with heparin rebound following surgery Teneja et al Can J Anesth 2009;56:7 Key point No relation between aptt and anti-xa activity following CPB Haemonetics Corp Bruce D. Spiess The aptt and INR-PT fibrinogen concentration tests and a number of other routine coagulation tests have been shown as having no predictive value (B50%) regarding hemorrhage after CPB Haemonetics Corp
6 Bruce D. Spiess The unstimulated TEG is one of the most sensitive tests for trace amounts of heparin Haemonetics Corp Extrinsic Pathway Extrinsic Pathway Tissue/Cell Defect F VIIa Ca 2+ F VII F Xa Ca 2+ F III (Tissue Thromboplastin) F X 12
7 Intrinsic Pathway Surface Contact Collagen FXII activator Intrinsic Pathway F XII F XIIa F XI Ca 2+ F XIa F IX Ca 2+ FIXa F X Ca 2+ F Xa 13 Common Pathway F Xa Prothrombin II Ca 2+ Thrombin IIa Fibrin polymers Fibrin monomers Fibrinogen 14
8 The Coagulation Cascade Intrinsic Pathway Surface Contact Collagen FXII activator Extrinsic Pathway Tissue/Cell Defect F XII F XIIa F VIIa Ca 2+ F VII F XI Ca 2+ F XIa F VIII F IX Ca 2+ F VIIIa Platelet Factor 3 F X FIXa Ca 2+ F Xa Ca 2+ F III (Tissue Thromboplastin) F X F Va F V 15 Crosslinked Fibrin Network F XIIIa Prothrombin II F XIII Fibrin polymers Ca 2+ Fibrin monomers Thrombin IIa Fibrinogen Yellow lines indicate positive feedback loops lost in isolated tests K EPL, LY30 = Platelet function R G = Clot Strength R = Reaction time to end of thrombin burst K = fibrin cross-linkage, fibrinogen function Angle = fibrinogen function MA = platelet function in mm G = MA converted to Kdynes/cm 2 LY30 = Lysis 30 minutes after MA reached 16
9 Heparin Effect Heparinase cup Plain cup *2.0* *0.4* Sensitivity - Testing for Presence of Heparin: Patient post-protamine and bleeding R value for KH = K Suggests no heparin present Green = kaolin with heparinase (KH) Black = kaolin only (K) R value for KH < K Suggests presence of heparin Haemonetics Corp
10 Heparin/LMWH 19 Normal TEG Analysis INCLUDES: Heparin LMWH Coumadin Arixtra Pradaxa Xarelto Factor Deficiency Fibrinogen Deficiency Platelet Function Clot Strength Lysis Surgical Bleeding from Hemostasis Hypercoagulability 20 EXCLUDES: Plavix Effient Brilinta Integrilin Reopro Aggrastat Pletal Persantine NSAIDs ASA Pathologic Platelet Inhibition
11 Example - CABG Case Heparin Challenges Haemonetics Corp Pt. #1 Baseline Haemonetics Corp
12 Pt. #1 Post Protamine Haemonetics Corp Pt. #1 Post Protamine 1 Tracing Overlay Reaction Time Sensitivity Haemonetics Corp
13 Pt. #1 Post Protamine 2 nd Dose Haemonetics Corp Pt. #1, 2hrs Later ICU (more protamine given) Haemonetics Corp
14 Pt. #1, 8hrs Later Haemonetics Corp Publication Date June Haemonetics Corp
15 Published Papers Altogether 170 papers were identified using the reported search strategy of which 14 represented the best evidence on the topic Haemonetics Corp Conclusion We conclude that thrombelastography may be useful in predicting patients who are likely to bleed postoperatively but more importantly, it can guide transfusion therapy algorithms in the bleeding cardiac surgical patient resulting in significant decreases in blood and blood component transfusion requirements Haemonetics Corp
16 Case Study: Reducing Allogeneic Blood Use Total $ Reduction 58% Transfused Product Cost: 30 patients before TEG monitoring vs. 30 patients after TEG monitoring (Data obtained from Harris Methodist H-E-B Hospital). 31 HCA: St. David s South Austin Medical Center Number of Patients Receiving Platelet Transfusions Total Patients Patients who received a platelet transfusion (Pre-TEG ) 2009 (Post TEG ) 58% received plt transfusion 32% received plt transfusion 26% decrease in number of patients receiving a platelet transfusion.
17 Risk Stratification w/ TEG Analyzer Haemonetics Corp Assessing Risk of Thrombosis Using TEG System Gurbel et al. J Am Coll Cardiol 2005;46: patients undergoing percutaneous coronary intervention (PCI) 100% on aspirin and clopidogrel (84%) TEG used to risk stratify for post-pci events Ischemic events were significantly associated (p < 0.001) by elevated pre and post-treatment MA (> 65) McCrath et al. Anesth Analg 2005;100: general surgery population TEG performed immediately after surgery 10 patients (4.2%) had 12 postoperative thrombotic events MA > 68 was predictive of thrombotic complications (p+ 0.01) (8.4% vs. 1.4%) Sources: 1 Gurbel et al. J Am Coll Cardiol 2005; 46: McCrath DJ et al. Anesth Analg Haemonetics Corp
18 Risk Stratification Thrombotic Events McCrath D et al. Anesth Analg 2005; 100:1576 Bliden KP et al. ACC Meeting 2005 When controlling for gender, race, age and ISS, elevated ma at admission was an independent predictor of PE with an odds ration of 3.5 for ma > 65 and 5.8 for ma > Haemonetics Corp
19 PlateletMapping Assay Monitoring Platelet Inhibition and Baseline Platelet Function PlateletMapping Assay What is it? Measures the effect of antiplatelet agents on platelet function Measures the patient s maximum platelet function as a reference point Measures the percentage of inhibition relative to the patient s reference point Measures the percentage of inhibition related to other causes: i.e. herbal supplements 38
20 PlateletMapping Assay What Clinical Questions Does It Answer? Pre-Op Does the patient have the potential to bleed during or after the cardiac procedure due to platelet inhibition Should we wait 5-7 Days (or less) for surgery if the patient is on an inhibitor? Should the patient potentially be put on a higher dose of the inhibitor? Post Op When there is a Normal TEG reading and the patient is bleeding Von Willebrands: R/O with DDAVP Surgical Bleed: R/O Prolene Platelet Inhibition as determined by Platelet Mapping Assay 39 Thrombelastograph Parameters R (min) - Time to initial fibrin formation induced by thrombin MA Thrombin - Maximum clot strength induced by thrombin MA Fibrin - Maximum contribution of fibrin only to MA MA ADP or A.A - Measures ADP or arachidonic acid stimulated clot strength R 0 Minutes 40
21 Pre-Op/ PlateletMapping Assay 41 Why PlateletMapping Assay? Personalized Platelet Therapy Patient A: 50% platelet inhibition does not provide sufficient reduction of the risk of a thrombotic or ischemic event Patient B: 50% platelet inhibition provides antithrombotic protection without risk of bleeding Patient C: 50% platelet inhibition increases risk of bleeding 42
22 Meds Affecting PlateletMapping Assay Platelet Inhibition GPIIb/IIIa ADP TXA 2 Reopro Plavix ASA Integrilin Persantine Aggrastat Toradol Effient Ticlid Effient Brilinta 43 Before Platelet Inhibitor (ADP) 44
23 After Platelet Inhibitor (ADP) Plavix, Effient, Ticlid, Brilinta, Integrilin, Aggrastat, Reopro, Persantine, Toradol, Pletal, Pathologic inhibition 45 Plavix, Effient, Ticlid, Brilinta, Integrilin, Aggrastat, Reopro, Persantine, Toradol, Pletal, Pathologic inhibition 46
24 Platelet Function Monitoring: Recommendations 2011 Areas of Major Revision 1. Management of dual anti-platelet therapy before operation a. POC testing for platelet ADP responsiveness is reasonable to identify Plavix non-responders who are candidates for early coronary revascularization; these might not require a 5 day wait (Level of evidence C) Timing of Surgery Circulation: Cardiovascular Interventions Platelet Function Measurement Based Strategy to Reduce Bleeding and Waiting Time In Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery: The TARGET- CABG Pilot Study Elizabeth Mahla, Thomas Suarez, Kevin P Bliden, Peter Rehak, Helfried Metzler, Alejandro Sequeira, Peter Cho, Jeffery Sell, John Fan, Mark Antonino, Udaya S Tantry, and Paul Gurbel Key points 1. Prospective, single center, unblinded investigation of two groups of patients who had preop PlateletMapping undergoing elective on-pump CABG: Clopidogrel treated vs Clopidogrel naïve Schedule for clopidogrel treated: 3 subsets 1. MA ADP > 50 mm = OR within 1 day 2. MA ADP = OR in 3-5days 3. MA ADP < 35 = OR after 5 days 2. This strategy was associated with the same amount of bleeding as in clopidogrel naïve patients and ~50% shorter waiting time than recommended in the current guidelines (2.7days vs 5 days) Circ Cardiovasc Interv. 2012;5: Haemonetics Corp
25 TARGET Study - Wait Time Impact TEG MA (ADP) > 50mm 35 50mm < 35mm Within 1 day Wait 3 5 days Wait 5 days N = 27 (31%) N = 42 (49%) N = 17 (20%) Average wait time was reduced by approximately 50% with no increase in bleeding, transfusions, or MACE (major adverse cardiac event) Haemonetics Corp PlateletMapping Assay TEG Analysis: MA 75.0 MA THROMBIN (complete activation) 20.7 MA ADP or MA AA (activation of non-inhibited platelets) 10.0 MA FIBRIN (no activation) % Inhibition = 83.5 % Aggregation = 16.5 % inhibition = 100 [(MA pi -MA f )/(MA t -MA f ) X 100] Haemonetics Corp
26 PlateletMapping Assay TEG Analysis: Clopidogrel Resistance MA THROMBIN MA ADP 10.0 MA FIBRIN % Inhibition = 8.5 % Aggregation = 91.5 % inhibition = 100 [(MA pi -MA f )/(MA t -MA f ) X 100] Haemonetics Corp PlateletMapping Assay TEG Analysis: Plavix MA THROMBIN MA ADP MA FIBRIN Haemonetics Corp
27 Haemonetics Corp Haemonetics Corp
28 Haemonetics Corp Haemonetics Corp
29 Pathologic Platelet Inhibition Not drug-induced May be due to foods or neutraceuticals May be underlying pathology May impact platelet activation or aggregation It is real, and should be considered for risk 57 Platelet Mapping Assay INCLUDES: HEMOSTASIS Hypercoagulability Lysis Surgical Bleeding from Hemostasis Factor Deficiency Fibrinogen Function Platelet 58 Function PLATELET MAPPING INTERVENTION Shows percent platelet inhibition due to: Interventional Treatment Pathologic Inhibition DRUGS: Heparin LMWH Coumadin Arixtra Pradaxa Xarelto Plavix Effient Ticlid Brilinta Reopro Integrilin Aggrastat ASA NSAIDs
30 Case Study Root Replacement Valve Haemonetics Corp Baseline (Secondary Fibrinolysis) 60
31 PlateletMapping Assay ADP Shows little inhibition AD P A KH 61 PlateletMapping Assay AA Shows full inhibition AA A KH 62
32 Rewarm TEG results suggest no products needed INR 3.4 (Usually 6-8 FFP given) 63 Post Protamine RT RT H Full reversal of Heparin. DDAVP given. No products given 64
33 Jehovah s Witness Platelet Mapping application 65 Outpatient ADP Mapping 66
34 Outpatient AA Mapping 67 Jehovah s Witness Decision was made to delay surgery for 5 days 2011 Haemonetics Corp. COMPANY CONFIDENTIAL
35 Pre-Op ADP Mapping 69 Pre-Op AA Mapping 70
36 71 Questions? THANK YOU AMSECT NABM!!
Hemostasis analyzer system
Hemostasis analyzer system Providing fast, actionable results to help you reduce risks, complications and costs Get the whole picture with TEG Hemostasis analyzer system For more than forty years, hospitals
More informationNew Oral Anticoagulants
Laboratory Monitoring of New Oral Anticoagulants.....What you need to know Rita Selby MD Medical Director, Coagulation Laboratories Uniersity Health Network & Sunnybrook HSC Uniersity of Toronto The 15
More informationGUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY
BLOOD CONSERVATION STRATEGIES IN CARDIAC SURGERY: MORE IS BETTER GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY DIMITRIOS V. AVGERINOS MD, PhD, FACS, FACC Department of Cardiac Surgery,
More informationReversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know. Ronald Walsh, MD Chief Medical Officer Community Blood Services
Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know Ronald Walsh, MD Chief Medical Officer Community Blood Services HEMOSTATIC PROCESS Initiation and formation of the platelet plug
More informationCritical Bleeding Reversal Protocol
Critical Bleeding Reversal Protocol Coagulopathy, either drug related or multifactorial, is a major contributing factor to bleeding related mortality in a variety of clinical settings. Standard therapy
More informationLAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options
LAMC Reversal Agent Guideline for Anticoagulants 2013 Medication resolution of hemostasis (hrs) Intervention Administration Instructions Heparin 3-4 Protamine 1mg IV for every 100 units of heparin Slow
More informationAnticoagulation and Reversal
Anticoagulation and Reversal John Howard, PharmD, BCPS Clinical Pharmacist Internal Medicine Affiliate Associate Clinical Professor South Carolina College of Pharmacy Disclosures I have no Financial, Industry,
More informationLaboratory Testing in Patients on Novel Oral Anticoagulants (NOACs)
Laboratory Testing in Patients on Novel Oral Anticoagulants (NOACs) Dr. Art Szkotak artur.szkotak@albertahealthservices.ca University of Alberta Hospital Edmonton, AB NOACs Direct Thrombin Inhibitors (DTI):
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationNew Anticoagulants: What to Use What to Avoid
New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA
More informationThrombin Formation for Children on Lovenox. Steven Ignell, BA
Thrombin Formation for Children on Lovenox Steven Ignell, BA Definitions Anticoagulation Historically this refers to inhibiting thrombin formation Measured by PTT, INR, anti-xa Hypo and hypercoagulation
More informationAn#- Coagulant An#- Thrombo#c An#- Platelet Drugs
An#- Coagulant An#- Thrombo#c An#- Platelet Drugs 1 ANTICOAGULANT CLASSES INHIBITORS OF CLOTTING FACTOR SYNTHESIS WARFARIN (COUMADIN ) Rivaroxaban (Xarelto ) INHIBITORS OF THROMBIN HEPARIN, LEPIRUDIN (REFLUDAN
More informationMCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants
MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013 Anticoagulants Anticoagulants are agents that prevent the formation of blood clots. Before we can talk about
More informationNote: Page numbers in italics indicate figures. Page numbers followed by a t indicate tables.
INDEX Note: Page numbers in italics indicate figures. Page numbers followed by a t indicate tables. Acquired bleeding disorders, 37-57 acquired combined inhibitor to factor V and thrombin, 55 acquired
More informationLABORATORY DIAGNOSIS OF BLEEDING DISORDERS
LABORATORY DIAGNOSIS OF BLEEDING DISORDERS Secondary Hemostasis CIRCULATORY SYSTEM Low volume, high pressure system Efficient for nutrient delivery to tissues Prone to leakage 2º 2 to endothelial surface
More informationOAC and NOAC with or without platelet inhibition
Zürich 11.06.2015 Preoperative antithrombotic management OAC and NOAC with or without platelet inhibition Miodrag Filipovic miodrag.filipovic@kssg.ch Anästhesiologie & Intensivmedizin Case 1 76 yr old
More informationGuidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults
Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults Purpose: To be used as a common tool for all practitioners involved in the care of patients
More informationWarfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in
More informationDisclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU
New Agents for Treatment of DVT Disclosure PI Adopt and Amplify trials Mark Oliver, MD, RVT, RPVI,FSVU BMS and Pfizer Speaker VTE Venous Thromboembolism Recognized DVT s New : 170,000 Recurrent : 90,000
More informationManaging Anticoagulants, Antiplatelets, and NSAIDS in the Interventional Radiology Setting. Amy Huggins, BSN, RN
Managing Anticoagulants, Antiplatelets, and NSAIDS in the Interventional Radiology Setting Amy Huggins, BSN, RN Objectives 1 2 3 4 5 Recognize bleeding risk based on classes of IR procedures Differentiate
More informationDuration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
More informationANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head
ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More information510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE AND INSTRUMENT TEMPLATE
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE AND INSTRUMENT TEMPLATE A. 510(k) Number: K041502 B. Purpose for Submission: To change the name of a previously cleared analyzer, and
More informationXabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center
Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center DISCLOSURES No relevant financial disclosures I will
More informationXarelto and the New Orals
Xarelto and the New Orals in the ER Peter L. Gross MD M.D., MSc M.Sc., FRCP(c) Associate Professor Thrombosis and Atherosclerosis Research Institute McMaster University Thrombosis Clinic Director, Juravinski
More informationEMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults. February, 2013
EMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults February, 2013 1 Quick Index To Reversal Recommendations Anti-Platelet Medications Page P2Y12
More informationProstate Assessment Pathway Prostate Biopsy Alerts
Prostate Assessment Pathway Prostate Biopsy Alerts Guidelines for the Management of Patient Preparation, Medications and Complications July 2015 Table of Contents Roles and Responsibilities. 1 SECTION
More informationThe Brave New (Anticoagulant) World
The Brave New (Anticoagulant) World Diane M. Birnbaumer, M.D., FACEP Emeritus Professor of Medicine University of California, Los Angeles Senior Clinical Educator Department of Emergency Medicine Harbor-UCLA
More informationHigh Risk Emergency Medicine
High Risk Emergency Medicine Minor Head Injuries in Patients on Oral Anticoagulants David Thompson, MD, MPH Assistant Professor Department of Emergency Medicine No relevant financial relationships to disclose
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationUpdate on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD
Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix
More informationPer Morten Sandset p.m.sandset@medisin.uio.no. Hemostasis parameters and medication prior to radiological interventions
Per Morten Sandset p.m.sandset@medisin.uio.no Hemostasis parameters and medication prior to radiological interventions The challenge Familial or acquired defects in the hemostatic system that dispose for
More informationUSE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN)
USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals:
More informationTitle of Guideline. Thrombosis Pharmacist)
Title of Guideline Contact Name and Job Title (author) Guideline for patients receiving Rivaroxaban (Xarelto ) requiring Emergency Surgery or treatment for Haemorrhage Julian Holmes (Haemostasis and Thrombosis
More informationHemostas under graviditet och förlossning. Ove Karlsson Sahlgrenska Universitetssjukhuset
Hemostas under graviditet och förlossning Ove Karlsson Sahlgrenska Universitetssjukhuset Handledare Margareta Hellgren, professor Obstetriska kliniken, Område 1 Sahlgrenska Universitetssjukhuset Anders
More informationA Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs
A Patient s Guide to Primary and Secondary Prevention of PATIENT EDUCATION GUIDE What Is Cardiovascular Disease? Cardiovascular disease (CVD) is a broad term that covers any disease of the heart and circulatory
More informationObjectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More informationEast Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
More informationAnticoagulation before and after cardioversion; which and for how long
Anticoagulation before and after cardioversion; which and for how long Sameh Samir, MD Cardiovascular medicine dept. Tanta faculty of medicine Atrial fibrillation goals of management Identify and treat
More informationBleeding disorders or haemorrhagic diatheses are a group of disorders characterised by defective haemostasis with abnormal bleeding.
Bleeding disorders or haemorrhagic diatheses are a group of disorders characterised by defective haemostasis with abnormal bleeding. Bleeding may be spontaneous in the form of small haemorrhages into the
More informationModule 1: Orthopedic Surgery: Disease State
XARELTO Product Brief ORS Rivaroxaban tablets Course Summary Module 1: Orthopedic Surgery: Disease State Orthopedic Surgery: Overview Pain and altered function of the hip and knee, due to conditions such
More informationCardiology Medications New Drugs, New Guidelines
Cardiology Medications New Drugs, New Guidelines Ken Kester, PharmD, JD Pharmacy Team Leader Nebraska Heart Hospital August 4, 2014 Cardiology Medications Objectives The attendee will understand Indications,
More informationSession 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:
More informationNew Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET Departments of Gastroenterology and Hepatology,
More informationNew Anticoagulants: When and Why Should I Use Them? Disclosures
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
More informationHow To Understand The History Of Analgesic Drugs
New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century David Stewart, PharmD, BCPS Associate Professor of Pharmacy Practice East Tennessee State University
More informationDISCLOSURES CONFLICT CATEGORY. No conflict of interest to disclose
DISCLOSURES CATEGORY Employment Research support Scientific advisory board Consultancy Speakers bureau Major stockholder Patents Honoraria Travel support Other CONFLICT No conflict of interest to disclose
More informationAnticoagulation Essentials! Parenteral and Oral!
Anticoagulation Essentials! Parenteral and Oral! Anti-Xa and Anti-IIa! Parenteral Anticoagulants! Heparin family (indirect anti-xa and anti-iia):! UFH! LMWH (enoxaparin, fondaparinux)! Direct thrombin
More informationWhat we all Needs to Know about New and Old Anticoagulant and Antiplatelet Drugs. None related to this presentation 11/22/2012
What we all Needs to Know about New and Old Anticoagulant and Antiplatelet Drugs Marvin A Wayne, MD, FACEP, FAAEM Associate Clinical Professor University of Washington, EMS Medical Director Whatcom County,
More informationLupus anticoagulant Pocket card
Lupus anticoagulant Pocket card Issue number 5 2012 Antiphospholipid Syndrome 1 The antiphospholipid syndrome (APS) is diagnosed in patients with recurrent thromboembolic events and /or pregnancy loss
More informationThe Anticoagulated Patient A Hematologist s Perspective
The Anticoagulated Patient A Hematologist s Perspective Deborah M. Siegal MD MSc FRCPC Clinical Scholar Division of Hematology and Thromboembolism Thrombosis Canada Research Fellow McMaster University
More informationAntiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty
Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor
More information5/21/2012. Perioperative Use Issues. On admission: During hospitalization:
Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA claudia.swenson@cwhs.com Dabigatran and Rivaroxaban:
More informationReview of Newer Antiplatelets, Antithrombotics and Reversal
Review of Newer Antiplatelets, Antithrombotics and Reversal Ravi Sarode, MD Professor of Pathology Chief of Pathology and Medical Director of Clinical Laboratory Services Director, Transfusion Medicine
More informationAntithrombotic therapy
Orthogeriatrics Clinical Summary Document Antithrombotic therapy Topics Preexisting anticoagulation and timing of surgery Reversal of anticoagulation Perioperative thromboprophylaxis When should we be
More informationNnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment
More informationDr Gordon Royle Haematologist, Middlemore Hospital
The New Oral Anticoagulants (NOACs) Dr Gordon Royle Haematologist, Middlemore Hospital Disclaimers Boehringer-Ingelheim Bayer Sanofi Douglas Pharmaceuticals Preventing disasters: lessons learned A cautionary
More informationAnticoagulation Therapy Update
Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2
More informationDisclosure. Outline. Objectives. I have no actual or potential conflict of interest in relation to this presentation.
Disclosure I have no actual or potential conflict of interest in relation to this presentation. Sarah Lombardo, MD., MSc. General Surgery, University of Utah September 9, 2015 Objectives Outline Recognize
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationBlood products and pharmaceutical emergencies
Blood products and pharmaceutical emergencies Kasey L. Bucher PharmD, BCPS Clinical Specialist, Emergency Medicine Mercy Health Saint Mary s September 12, 2013 Disclosures None significancemagazine.com
More informationRivaroxaban (Xarelto ) by
Essentia Health Med Moment Short Video Tune-Up A brief overview of a new medication, or important new medication information Rivaroxaban (Xarelto ) by Richard Mullvain RPH BCPS (AQC) Current - August 2011
More informationStop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery
Stop the Bleeding: Management of Drug-induced Coagulopathy Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery Objectives Discuss contemporary management of warfarin reversal in patients
More informationCilostazol versus Clopidogrel after Coronary Stenting
Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background
More informationAbnormal Basic Coagulation Testing Laboratory Testing Algorithms
Global Coagulation Testing Abnormal Basic Coagulation Testing Laboratory Testing Algorithms Jeffrey S. Jhang, M.D. No single global laboratory test Bleeding history is the strongest predictor of bleeding
More informationPoint-of-care testing Thrombelastography and platelet transfusion
Point-of-care testing Thrombelastography and platelet transfusion Gisela Scharbert Department of Anesthesiology, Intensive Care and Pain Management Vienna Medical University, Austria Trauma-induced coagulopathy
More informationCHADS score of 5 or 6 Recent (within 3mo) stroke or TIA Rheumatic valvular heart disease CHADs score of 3 or 4
LAMC Department of Pharmacy Services: ANTICOAGULATION: Surgical Intervention Table 1: Classification of Surgical interventions according to bleeding risk t required to discontinue anticoagulation Dental
More informationOptimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015
Optimizing Anticoagulation Selection for Your Patient C. Andrew Brian MD, FACC NCVH 2015 Who Needs to Be Anticoagulated and What is the Patient s Risk? 1. Atrial Fibrillation ( nonvalvular ) 2. What regimen
More informationAntithromboticthrombotic Monitoring
Introduction to Antithromboticthrombotic Monitoring 1 Topics What is thrombosis, and why is it significant? Coagulation Cascade Pathways of coagulation, anticoagulation, and fibrinolysis Thrombophilia
More informationHot Topics: Current PFO Recommendations and Loop Monitoring/Cryptogenic Stroke.
Hot Topics: Current PFO Recommendations and Loop Monitoring/Cryptogenic Stroke. Favoriteplus.com www.heartrhythmcharity.org.uk www.forbes.com Victor J. Mazza, MD Assistant Professor of Medicine Cardiology,
More informationNew Oral Anticoagulants Markets
Brochure More information from http://www.researchandmarkets.com/reports/2497048/ New Oral Anticoagulants Markets Description: Anticoagulants decrease the ability of the blood to create harmful blood clots
More informationCardiology Medications New Drugs, New Guidelines
Cardiology Medications New Drugs, New Guidelines Ken Kester, PharmD, JD Pharmacy Team Leader Nebraska Heart Hospital August 4, 2014 CARDIOLOGY MEDICATIONS Objectives The attendee will understand Indications,
More informationTraditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
More informationClinical Guideline N/A. November 2013
State if the document is a Trust Policy/Procedure or a Clinical Guideline Clinical Guideline Document Title: Document Number 352 Version Number 1 Name and date and version number of previous document (if
More informationYvette Marie Miller, M.D. Executive Medical Officer American Red Cross October 20, 2012 45 th Annual Great Lakes Cancer Nursing Conference Troy, MI
Yvette Marie Miller, M.D. Executive Medical Officer American Red Cross October 20, 2012 45 th Annual Great Lakes Cancer Nursing Conference Troy, MI Overview of Hematology, http://www.nu.edu.sa/userfiles/mhmorsy/h
More informationFinancial Disclosures. Learning Objectives 05/06/2015. None
ANTITHROMBOTIC MANAGEMENT PRE AND POST ENDOSCOPY Dustin Loomes, MD, FRCPC, Advanced training in Inflammatory Bowel Disease University of Alberta Hospital, Edmonton, AB St. Paul s Hospital, Vancouver, BC
More informationManagement of Patients on Anticoagulants. Haemostasis. Coagulation cascade. Cell-based model 19/11/2013
Management of Patients on Anticoagulants National Coal Mining Museum 11 Nov 2013 Navneet Lad StR Special Care Dentistry Aims: Discuss the different anti-platelet drugs available. Discuss the new generation
More informationPrescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
More informationImpact of new (direct) oral anticoagulants in patient blood management
Impact of new (direct) oral anticoagulants in patient blood management Yulia Lin, MD, FRCPC, CTBS Transfusion Medicine & Hematology, Sunnybrook Health Sciences Centre Dept of Laboratory Medicine & Pathobiology,
More informationBreaking Old Habits: Use of the New Oral Anticoagulants in Clinical Practice
Breaking Old Habits: Use of the New Oral Anticoagulants in Clinical Practice Antiplatelets and oral anticoagulants Aspirin Plavix Prasugrel Ticagrelor Apixaban Rivaroxaban Dabigatran- Direct thrombin inhibitor
More informationTo aid practitioners in prescribing unfractionated heparin and low-molecular-weight heparins to patients.
UNFRACTIONATED HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To aid practitioners in prescribing unfractionated heparin and low-molecular-weight
More informationDrugs that alter. blood coagulation. Brush up on your knowledge of these potentially life-saving drugs. By Amy M. Karch, RN, MS
PHARMACOLOGY REVIEW: Drugs that alter blood coagulation Brush up on your knowledge of these potentially life-saving drugs. By Amy M. Karch, RN, MS THE VASCULAR SYSTEM delivers oxygen and nutrients to all
More information23/06/2014. Implications for the Gastroenterologist. No financial interests I am not a hematologist
Implications for the Gastroenterologist Dr. Daniel Sadowski Royal Alexandra Hospital Edmonton, Ab. No financial interests I am not a hematologist 65 y.o. male referred for iron deficiency anemia (FIT positive)
More informationNew oral anticoagulants and antiplatelets: Where do they fit? Meredith Hollinger, PharmD BCPS
New oral anticoagulants and antiplatelets: Where do they fit? Meredith Hollinger, PharmD BCPS Clinical Pharmacy Specialist, Cardiology September 2012 Objectives Describe the mechanisms of action for novel
More informationOral Anticoagulants and Dental Procedures
Oral Anticoagulants and Dental Procedures Ashley N. Castelvecchi, PharmD; Lamonica N. Crump, PharmD Continuing Education Units: 1 hour This course will discuss the available anticoagulant and antiplatelet
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationNew anticoagulants: Monitoring or not Monitoring? Not Monitoring
The 2 nd World Congress on CONTROVERSIES IN HEMATOLOGY (COHEM) Barcelona, Spain September 6 8, 2012 New anticoagulants: Monitoring or not Monitoring? Not Monitoring Anna Falanga, MD Immunohematology and
More informationDr Gordon Royle Haematologist, Middlemore Hospital
The New Oral Anticoagulants (NOACs) Dr Gordon Royle Haematologist, Middlemore Hospital Disclaimers Boehringer-Ingelheim Bayer Sanofi Douglas Pharmaceuticals Preventing disasters: lessons learned A cautionary
More informationHeparin Induced Thrombocytopenia
Heparin Induced Thrombocytopenia Ann-Marie Liberman B.Sc.Phm., ACPR Clinical Pharmacist, Cardiac Surgery Clinical Trials Pharmacist Royal Columbian Hospital Fraser Health Disclosure Participated in research
More informationThe New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences
The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences Center September 25, 2015 Question: With which of the
More informationGetting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot
Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:
More informationQUICK REFERENCE. Mary Cushman 1 Wendy Lim 2 Neil A Zakai 1. University of Vermont 2. McMaster University
QUICK REFERENCE Clinical Practice Guide on Antithrombotic Drug Dosing and Management of Antithrombotic Drug- Associated Bleeding Complications in Adults February 2014* Mary Cushman 1 Wendy Lim 2 Neil A
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationL'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy ISO 9001
L'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy Scientific Advances and Cardiovascular Mortality Nabel and
More informationDUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania
DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen
More informationTranexamic Acid. Tranexamic Acid. Overview. Blood Conservation Strategies. Blood Conservation Strategies. Blood Conservation Strategies
Overview Where We Use It And Why Andreas Antoniou, M.D., M.Sc. Department of Anesthesia and Perioperative Medicine University of Western Ontario November 14 th, 2009 Hemostasis Fibrinolysis Aprotinin and
More informationTO: HELENA SALES, POC SPECALISTS, INTERNATIONAL DISTRIBUTORS FROM: HELENA HEMOSTASIS/POINT OF CARE SUBJECT: ROUND-UP DATE: 11/10/2010
TO: HELENA SALES, POC SPECALISTS, INTERNATIONAL DISTRIBUTORS FROM: HELENA HEMOSTASIS/POINT OF CARE SUBJECT: ROUND-UP DATE: 11/10/2010 General News It has been a while since the last issue but every time
More information